Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma

References

• Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785–997.
   PubMed Web of Science ®Google Scholar
• Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326–338.
   PubMed Web of Science ®Google Scholar
• Lammens T, Li J, Leone G, et al. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol. 2009;19(3):111–118.
   PubMed Web of Science ®Google Scholar
• Schaal C, Pillai S, Chellappan SP. The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis. Adv Cancer Res. 2014;121:147–182.
   PubMed Web of Science ®Google Scholar
• Shats I, Deng M, Davidovich A, et al. Expression level is a key determinant of E2F1-mediated cell fate. Cell Death Differ. 2017;24(4):626–637.
   PubMed Web of Science ®Google Scholar
• Teixeira LK, Wang X, Li Y, et al. Cyclin E deregulation promotes loss of specific genomic regions. Curr Biol. 2015;25(10):1327–1333.
   PubMed Web of Science ®Google Scholar
• Wu M, Seto E. E2f ZJ. 1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells. Oncotarget. 2015;6(13):11252–11263.
   PubMedGoogle Scholar
• Araki K, Kawauchi K, Sugimoto W, et al. Mitochondrial protein E2F3d, a distinctive E2F3 product, mediates hypoxia-induced mitophagy in cancer cells. Commun Biol. 2019;2(1):3.
   PubMedGoogle Scholar
• Kent LN, Rakijas JB, Pandit SK, et al. E2f8 mediates tumor suppression in postnatal liver development. J Clin Invest. 2016;126(8):2955–2969.
   PubMed Web of Science ®Google Scholar
• Logan N, Graham A, Zhao X, et al. E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene. 2005;24(31):5000–5004.
   PubMed Web of Science ®Google Scholar
• Liban TJ, Thwaites MJ, Dick FA, et al. Structural Conservation and E2F Binding Specificity within the Retinoblastoma Pocket Protein Family. J Mol Biol. 2016;428(20):3960–3971.
   PubMed Web of Science ®Google Scholar
• Liu H, Tang X, Srivastava A, et al. Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. Nat Cell Biol. 2015;17(8):1036–1048.
   PubMed Web of Science ®Google Scholar
• Saenz-Ponce N, Pillay R, De Long LM, et al. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Sci Transl Med. 2018;10(447):eaar7223.
   PubMed Web of Science ®Google Scholar
• Lan W, Bian B, Xia Y, et al. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments. Sci Rep. 2018;8(1):8330.
   PubMedGoogle Scholar
• Hollern DP, Honeysett J, Cardiff RD, et al. The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol Cell Biol. 2014;34(17):3229–3243.
   PubMed Web of Science ®Google Scholar
• Jin DH, Kim Y, Lee BB, et al. Metformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells. Oncotarget. 2017;8(60):101509–101519.
   PubMedGoogle Scholar
• Park SA, Platt J, Lee JW, et al. E2F8 as a Novel Therapeutic Target for Lung Cancer. J Natl Cancer Inst. 2015;107(9):djv151.
   PubMedGoogle Scholar
• Lee SR, Roh YG, Kim SK, et al. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer. Clin Cancer Res. 2015;21(23):5391–5403.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573.
   PubMed Web of Science ®Google Scholar
• Palazzo M, Templeton M. Statistical interpretation of Kaplan–Meier curves. Intensive Care Med. 2007;33(12):2235.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Hu X, Martinez-Ledesma E, Zheng S, et al. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017;19(6):786–795.
   PubMed Web of Science ®Google Scholar
• Obuchowski NA, Bullen JA. Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine. Phys Med Biol. 2018;63(7):07tr1.
   Web of Science ®Google Scholar
• Qi-Dong X, Yang X, Lu JL, et al. Development and validation of a nine-redox-related long noncoding RNA Signature in renal clear cell carcinoma. Oxid Med Cell Longevity. 2020;2020:6634247.
   PubMed Web of Science ®Google Scholar
• Hu LP, Zhang XX, Jiang SH, et al. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Clin Cancer Res. 2019;25(4):1318–1330.
   PubMed Web of Science ®Google Scholar
• Bates A, Gonzalez-Viana E, Cruickshank G, et al. Primary and metastatic brain tumours in adults: summary of NICE guidance. BMJ. 2018;362:k2924.
   PubMedGoogle Scholar
• Chang SM, Messersmith H, Ahluwalia M, et al. Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. J Clin Oncol. 2019;37(13):1130–1135.
   PubMed Web of Science ®Google Scholar
• Wen PY, Weller M, Lee EQ, et al. Glioblastoma in Adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro Oncol. 2020;24:noaa106.
   Web of Science ®Google Scholar
• Brandner S, Jaunmuktane Z. Neurological update: gliomas and other primary brain tumours in adults. J Neurol. 2018;265(3):717–727.
   PubMed Web of Science ®Google Scholar
• Cheng M, Zhang ZW, Ji XH, et al. Super-enhancers: a new frontier for glioma treatment. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188353.
   PubMed Web of Science ®Google Scholar
• Lin AJ, Campian JL, Hui C, et al. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol. 2018;136(2):403–411.
   PubMed Web of Science ®Google Scholar
• Patil CG, Walker DG, Miller DM, et al. Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas. Neurosurgery. 2019;85(4):641–649.
   PubMed Web of Science ®Google Scholar
• Shu HK, Julin CM, Furman F, et al. Overexpression of E2F1 in glioma-derived cell lines induces a p53-independent apoptosis that is further enhanced by ionizing radiation. Neuro Oncol. 2000;2(1):16–21.
   PubMed Web of Science ®Google Scholar
• Donaires FS, Godoy PR, Leandro GS, et al. E2F transcription factors associated with up-regulated genes in glioblastoma. Cancer Biomark. 2017;18(2):199–208.
   PubMed Web of Science ®Google Scholar
• Shen ZG, Liu XZ, Chen CX, et al. Knockdown of E2F3 Inhibits Proliferation, Migration, and Invasion and Increases Apoptosis in Glioma Cells. Oncol Res. 2017;25(9):1555–1566.
   PubMed Web of Science ®Google Scholar
• Yu H, Zhang D, Li Z, et al. E2F transcription factor 8 promotes proliferation and radioresistance in glioblastoma. Pathol Res Pract. 2020;216(8):153030.
   PubMed Web of Science ®Google Scholar
• Yin W, Wang B, Ding M, et al. Elevated E2F7 expression predicts poor prognosis in human patients with gliomas. J Clin Neurosci. 2016;33:187–193.
   PubMed Web of Science ®Google Scholar
• Thurlings I, Martinez-Lopez LM, Westendorp B, et al. Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer. Oncogene. 2017;36(6):829–839.
   PubMed Web of Science ®Google Scholar
• Chong JL, Tsai SY, Sharma N, et al. E2f3a and E2f3b contribute to the control of cell proliferation and mouse development. Mol Cell Biol. 2009;29(2):414–424.
   PubMed Web of Science ®Google Scholar
• Danielian PS, Friesenhahn LB, Faust AM, et al. E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene. 2008;27(51):6561–6570.
   PubMed Web of Science ®Google Scholar
• Kent LN, Bae S, Tsai SY, et al. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 2017;127(3):830–842.
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C, Mitlianga P, Fueyo J, et al. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res. 2001;61(18):6693–6697.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Z, Dong Y, et al. E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner. Life Sci. 2021;276:119412.
   PubMed Web of Science ®Google Scholar
• Clijsters L, Hoencamp C, Calis JJA, et al. Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs. Mol Cell. 2019;74(6):264–277.
   Web of Science ®Google Scholar
• Yuan R, Vos HR, Van Es RM, et al. Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest. EMBO J. 2018;37(5):e97877.
   PubMed Web of Science ®Google Scholar
• Polager S, Kalma Y, Berkovich E, et al. E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene. 2002;21(3):437–446.
   PubMed Web of Science ®Google Scholar
• Gujar AD, Le S, Mao DD, et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc Natl Acad Sci USA. 2016;113(51):8247–8256.
   Web of Science ®Google Scholar
• Shibata E, Kiran M, Shibata Y, et al. Two subunits of human ORC are dispensable for DNA replication and proliferation. Elife. 2016;5:e19084.
   PubMed Web of Science ®Google Scholar
• Muller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001;15(3):267–285.
   PubMed Web of Science ®Google Scholar
• Carvajal LA, Hamard PJ, Tonnessen C, et al. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev. 2012;26(14):1533–1545.
   PubMed Web of Science ®Google Scholar